liothyronine (cytomel) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rathyronine is racemic mixture of Liothyronine (L-Triiodothyronine) and D-Triiodothyronine. Liothyronine (traid name CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine. D-Triiodothyronine may be used to treatment hyperlipidemia, hypothyroidism, euthyroid goiters, ets. Unfortunately there are limited research related Rathyronine or D-Triiodothyronine activity.   NCATS

Chemistry

  • SMILES: N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
  • InChIKey: AUYYCJSJGJYCDS-LBPRGKRZSA-N
  • Mol. Mass: 650.9735
  • ALogP: 3.95
  • ChEMBL Molecules:
    liothyronine sodium  
    liothyronine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1896 - $261.3100

Australia

$0.4415
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( levothyroxine (Synthroid), liothyronine (cytomel) )

Alternative names

3,3',5-triiodo-l-thyronine | 3,5,3'-triiodo-l-thyronine | 3,5,3'triiodothyronine | 3,5,3'-triiodothyronine | 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-l-phenylalanine | cynomel | cytomel | euthroid-0.5 | euthroid-1 | euthroid-2 | euthroid-3 | l-3,5,3'-triiodothyronine | liothyronin | liothyronine | liothyronine sodium | liothyroninum | liotironina | l-t3 | o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-l-tyrosine | rathyronine | sodium liothyronine | t3 | t3 (liotrix) | tertroxin | thybon | thyrolar-0.25 | thyrolar-0.5 | thyrolar-1 | thyrolar-2 | thyrolar-3 | thyrolar-5 | tiodothyronine | tresitope | triiodothyronine | tri-iodothyronine | triiodothyronine,evans | triiodothyronine sodium, levo | triiodothyronine (t3 or liothyronine, active) (6-11%) | triostat

Organizations (66)

Research & Development (54)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (40)

Approved Indications (5)


 

Depression

Hyperthyroidism (approved 1956)

Hypothyroidism (approved 1956)

Myxedema

Thyroid Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Atrial Fibrillation (Phase 1)

Biomarkers (Phase 2)

Bipolar Disorder (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Early Phase 1)

Diabetes Mellitus (Phase 2)

Endocrine System Diseases (Phase 2)

Ependymoma (Phase 2)

Euthyroid Sick Syndromes (Phase 2)

Glioblastoma (Phase 2)

Gliosarcoma (Early Phase 1)

Head and Neck Neoplasms (Phase 1)

Healthy Volunteers (Phase 1/Phase 2)

Heart Defects, Congenital (Phase 3)

Heart Failure, Diastolic (Phase 1/Phase 2)

Heart Failure, Systolic (Phase 1/Phase 2)

Hyperlipidemias (Phase 4)

Hypopituitarism (Phase 4)

Hypothyroidism (Phase 4)

Insulin Resistance (Phase 2)

Medulloblastoma (Phase 2)

Metabolism (Phase 2)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Obesity (Phase 3)

Pneumonia (Phase 1/Phase 2)

Postoperative Complications (Phase 3)

Pulmonary Edema (Phase 1/Phase 2)

Quality of Life (Phase 4)

Respiratory Distress Syndrome (Phase 1/Phase 2)

Thyroid Cancer, Papillary (Phase 4)

Thyroid Diseases (Phase 2)

Thyroid Gland (Phase 2)

Thyroid Neoplasms (Phase 2)

Tricuspid Atresia (Phase 1)

Triiodothyronine (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 50
  • # of Trial Organizations: 54

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue